Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron supplementation optimization after Roux-en-Y gastric bypass
NL-OMON40886Phase 4Not yet recruiting
- Sponsor
- Rijnstate
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ferric carboxymaltose, ferrous fumarate and Ferrous gluconate in iron deficiency anemia (IDA) (3 arms), sponsored by Rijnstate. Primary endpoints: Serum ferritin at 6, 12, and 52 weeks, Serum iron at 6, 12, and 52 weeks and 3 more. Planned start Aug 2014; status: not yet recruiting.
02
Drugs
ferric carboxymaltoseferrous fumarateFerrous gluconate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON40886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40886.